IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v35y2017i1d10.1007_s40273-017-0545-x.html
   My bibliography  Save this article

A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models

Author

Listed:
  • John Brazier

    (University of Sheffield)

  • Roberta Ara

    (University of Sheffield)

  • Donna Rowen

    (University of Sheffield)

  • Helene Chevrou-Severac

    (Takeda Pharmaceuticals International AG)

Abstract

Generic preference-based measures (GPBMs) of health are used to obtain the quality adjustment weight required to calculate the quality-adjusted life year in health economic models. GPBMs have been developed to use across different interventions and medical conditions and typically consist of a self-complete patient questionnaire, a health state classification system, and preference weights for all states defined by the classification system. Of the six main GPBMs, the three most frequently used are the Health Utilities Index version 3, the EuroQol 5 dimensions (3 and 5 levels), and the Short Form 6 dimensions. There are considerable differences in GPBMs in terms of the content and size of descriptive systems (i.e. the numbers of dimensions of health and levels of severity within these), the methods of valuation [e.g. time trade-off (TTO), standard gamble (SG)], and the populations (e.g. general population, patients) used to value the health states within the descriptive systems. Although GPBMs are anchored at 1 (full health) and 0 (dead), they produce different health state utility values when completed by the same patient. Considerations when selecting a measure for use in a clinical trial include practicality, reliability, validity and responsiveness. Requirements of reimbursement agencies may impose additional restrictions on suitable measures for use in economic evaluations, such as the valuation technique (TTO, SG) or the source of values (general public vs. patients).

Suggested Citation

  • John Brazier & Roberta Ara & Donna Rowen & Helene Chevrou-Severac, 2017. "A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models," PharmacoEconomics, Springer, vol. 35(1), pages 21-31, December.
    • Handle: RePEc:spr:pharme:v:35:y:2017:i:1:d:10.1007_s40273-017-0545-x
    DOI: 10.1007/s40273-017-0545-x
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-017-0545-x
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-017-0545-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Méndez, Ildefonso & Abellán Perpiñán, Jose M. & Sánchez Martínez, Fernando I. & Martínez Pérez, Jorge E., 2011. "Inverse probability weighted estimation of social tariffs: An illustration using the SF-6D value sets," Journal of Health Economics, Elsevier, vol. 30(6), pages 1280-1292.
    2. Louise Longworth & Stirling Bryan, 2003. "An empirical comparison of EQ‐5D and SF‐6D in liver transplant patients," Health Economics, John Wiley & Sons, Ltd., vol. 12(12), pages 1061-1067, December.
    3. Samer A. Kharroubi & Anthony O'Hagan & John E. Brazier, 2005. "Estimating utilities from individual health preference data: a nonparametric Bayesian method," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 54(5), pages 879-895, November.
    4. Richard Norman & Paula Cronin & Rosalie Viney, 2013. "A Pilot Discrete Choice Experiment to Explore Preferences for EQ-5D-5L Health States," Applied Health Economics and Health Policy, Springer, vol. 11(3), pages 287-298, June.
    5. Rosalie Viney & Richard Norman & John Brazier & Paula Cronin & Madeleine T. King & Julie Ratcliffe & Deborah Street, 2014. "An Australian Discrete Choice Experiment To Value Eq‐5d Health States," Health Economics, John Wiley & Sons, Ltd., vol. 23(6), pages 729-742, June.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Roberta Ara & John Brazier & Tracey Young, 2017. "Recommended Methods for the Collection of Health State Utility Value Evidence in Clinical Studies," PharmacoEconomics, Springer, vol. 35(1), pages 67-75, December.
    2. Jonathan Karnon, 2017. "Heath State Utility Values for Cost-Effectiveness Models," PharmacoEconomics, Springer, vol. 35(1), pages 1-3, December.
    3. Michela Meregaglia & Elena Nicod & Michael Drummond, 2023. "The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(7), pages 1151-1216, September.
    4. Tessier, Philippe & Wolff, François-Charles, 2024. "On the ability of the SF-6D to capture the consequences of chronic illnesses on subjective well-being: Evidence from France," Social Science & Medicine, Elsevier, vol. 354(C).
    5. Roberta Ara & John Brazier & Tessa Peasgood & Suzy Paisley, 2017. "The Identification, Review and Synthesis of Health State Utility Values from the Literature," PharmacoEconomics, Springer, vol. 35(1), pages 43-55, December.
    6. Donna Rowen & John Brazier & Roberta Ara & Ismail Azzabi Zouraq, 2017. "The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment," PharmacoEconomics, Springer, vol. 35(1), pages 33-41, December.
    7. Nathan S. McClure & Mike Paulden & Arto Ohinmaa & Jeffrey A. Johnson, 2021. "Modifying the quality-adjusted life year calculation to account for meaningful change in health-related quality of life: insights from a pragmatic clinical trial," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1441-1451, December.
    8. Ângela Jornada Ben & Johanna M. Dongen & Aureliano Paolo Finch & Mohamed El Alili & Judith E. Bosmans, 2023. "To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(8), pages 1253-1270, November.
    9. Satar Rezaei & Abraha Woldemichael & Sina Ahmadi & Amjad Mohamadi Bolbanabad & Farman Zahir Abdullah & Bakhtiar Piroozi, 2021. "Comparing the properties of the EQ‐5D‐5L and EQ‐5D‐3L in general population in Iran," International Journal of Health Planning and Management, Wiley Blackwell, vol. 36(5), pages 1613-1625, September.
    10. Pickles, Kristen & Lancsar, Emily & Seymour, Janelle & Parkin, David & Donaldson, Cam & Carter, Stacy M., 2019. "Accounts from developers of generic health state utility instruments explain why they produce different QALYs: A qualitative study," Social Science & Medicine, Elsevier, vol. 240(C).
    11. Paul Schneider & Nancy Devlin & Ben van Hout & John Brazier, 2024. "Exploring health preference heterogeneity in the UK: Using the online elicitation of personal utility functions approach to construct EQ‐5D‐5L value functions on societal, group and individual level," Health Economics, John Wiley & Sons, Ltd., vol. 33(5), pages 894-910, May.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Bansback, Nick & Hole, Arne Risa & Mulhern, Brendan & Tsuchiya, Aki, 2014. "Testing a discrete choice experiment including duration to value health states for large descriptive systems: Addressing design and sampling issues," Social Science & Medicine, Elsevier, vol. 114(C), pages 38-48.
    2. Jing Wu & Shitong Xie & Xiaoning He & Gang Chen & Gengliang Bai & Da Feng & Ming Hu & Jie Jiang & Xiaohui Wang & Hongyan Wu & Qunhong Wu & John E. Brazier, 2021. "Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension," PharmacoEconomics, Springer, vol. 39(5), pages 521-535, May.
    3. Nicolas Krucien & Verity Watson & Mandy Ryan, 2017. "Is Best–Worst Scaling Suitable for Health State Valuation? A Comparison with Discrete Choice Experiments," Health Economics, John Wiley & Sons, Ltd., vol. 26(12), pages 1-16, December.
    4. Sullivan, Trudy & Hansen, Paul & Ombler, Franz & Derrett, Sarah & Devlin, Nancy, 2020. "A new tool for creating personal and social EQ-5D-5L value sets, including valuing ‘dead’," Social Science & Medicine, Elsevier, vol. 246(C).
    5. Brendan Mulhern & Nick Bansback & Arne Risa Hole & Aki Tsuchiya, 2017. "Using Discrete Choice Experiments with Duration to Model EQ-5D-5L Health State Preferences," Medical Decision Making, , vol. 37(3), pages 285-297, April.
    6. Brendan Mulhern & Richard Norman & Paula Lorgelly & Emily Lancsar & Julie Ratcliffe & John Brazier & Rosalie Viney, 2017. "Is Dimension Order Important when Valuing Health States Using Discrete Choice Experiments Including Duration?," PharmacoEconomics, Springer, vol. 35(4), pages 439-451, April.
    7. Edward J. D. Webb & John O’Dwyer & David Meads & Paul Kind & Penny Wright, 2020. "Transforming discrete choice experiment latent scale values for EQ-5D-3L using the visual analogue scale," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(5), pages 787-800, July.
    8. Arne Risa Hole & Richard Norman & Rosalie Viney, 2016. "Response Patterns in Health State Valuation Using Endogenous Attribute Attendance and Latent Class Analysis," Health Economics, John Wiley & Sons, Ltd., vol. 25(2), pages 212-224, February.
    9. Richard Norman & Rosalie Viney & John Brazier & Leonie Burgess & Paula Cronin & Madeleine King & Julie Ratcliffe & Deborah Street, 2014. "Valuing SF-6D Health States Using a Discrete Choice Experiment," Medical Decision Making, , vol. 34(6), pages 773-786, August.
    10. Brendan Mulhern & Richard Norman & Deborah J. Street & Rosalie Viney, 2019. "One Method, Many Methodological Choices: A Structured Review of Discrete-Choice Experiments for Health State Valuation," PharmacoEconomics, Springer, vol. 37(1), pages 29-43, January.
    11. Richard Norman & Rebecca Mercieca‐Bebber & Donna Rowen & John E. Brazier & David Cella & A. Simon Pickard & Deborah J. Street & Rosalie Viney & Dennis Revicki & Madeleine T. King & On behalf of the Eu, 2019. "U.K. utility weights for the EORTC QLU‐C10D," Health Economics, John Wiley & Sons, Ltd., vol. 28(12), pages 1385-1401, December.
    12. Brendan Mulhern & Richard Norman & Koonal Shah & Nick Bansback & Louise Longworth & Rosalie Viney, 2018. "How Should Discrete Choice Experiments with Duration Choice Sets Be Presented for the Valuation of Health States?," Medical Decision Making, , vol. 38(3), pages 306-318, April.
    13. Spencer, Anne & Rivero-Arias, Oliver & Wong, Ruth & Tsuchiya, Aki & Bleichrodt, Han & Edwards, Rhiannon Tudor & Norman, Richard & Lloyd, Andrew & Clarke, Philip, 2022. "The QALY at 50: One story many voices," Social Science & Medicine, Elsevier, vol. 296(C).
    14. Dennis A. Revicki & Madeleine T. King & Rosalie Viney & A. Simon Pickard & Rebecca Mercieca-Bebber & James W. Shaw & Fabiola Müller & Richard Norman, 2021. "United States Utility Algorithm for the EORTC QLU-C10D, a Multiattribute Utility Instrument Based on a Cancer-Specific Quality-of-Life Instrument," Medical Decision Making, , vol. 41(4), pages 485-501, May.
    15. Menglu Che & Feng Xie & Stephanie Thomas & Eleanor Pullenayegum, 2023. "Bayesian Models with Spatial Correlation Improve the Precision of EQ-5D-5L Value Sets," Medical Decision Making, , vol. 43(5), pages 587-594, July.
    16. Kontodimopoulos, Nick & Niakas, Dimitris, 2008. "An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy," Health Policy, Elsevier, vol. 86(1), pages 85-96, April.
    17. Knott, R. & Lorgelly, P. & Black, N. & Hollingsworth, B., 2016. "Differential item functioning in the EQ-5D: An exploratory analysis using anchoring vignettes," Health, Econometrics and Data Group (HEDG) Working Papers 16/14, HEDG, c/o Department of Economics, University of York.
    18. Marra, Carlo A. & Woolcott, John C. & Kopec, Jacek A. & Shojania, Kamran & Offer, Robert & Brazier, John E. & Esdaile, John M. & Anis, Aslam H., 2005. "A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis," Social Science & Medicine, Elsevier, vol. 60(7), pages 1571-1582, April.
    19. Brendan Mulhern & Richard Norman & John Brazier, 2021. "Valuing SF-6Dv2 in Australia Using an International Protocol," PharmacoEconomics, Springer, vol. 39(10), pages 1151-1162, October.
    20. Kharroubi, Samer & Brazier, John E. & O'Hagan, Anthony, 2007. "Modelling covariates for the SF-6D standard gamble health state preference data using a nonparametric Bayesian method," Social Science & Medicine, Elsevier, vol. 64(6), pages 1242-1252, March.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:35:y:2017:i:1:d:10.1007_s40273-017-0545-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.